期刊
BLOOD
卷 126, 期 9, 页码 1118-1127出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-12-618801
关键词
-
类别
资金
- New York State Stem Cell Science (NYSTEM) of the Gottesman Institute for Stem Cell [C029154]
- Albert Einstein Cancer Center Core [P30CA013330]
- National Institutes of Health, National Cancer Institute (NCI) [R01CA166429, R01CA142928]
- Medical Scientist Training Program (MSTP) [T32GM007288]
- National Heart, Lung, and Blood Institute (NHLBI) fellowship [F30HL117545, F30HL122085]
- Cellular and Molecular Biology and Genetics (CMBG) [T32GM007491]
- Leukaemia and Lymphoma Research of the United Kingdom
Poor clinical outcome of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has been attributed to failure of current chemotherapeutic regimens to target leukemic stem cells. We recently identified p21-activated kinase (PAK1) as a downstream effector molecule of H2.0-like homeobox (HLX), a gene functionally relevant for AML pathogenesis. In this study, we find that inhibition of PAK1 activity by small molecule inhibitors or by RNA interference leads to profound leukemia inhibitory effects both in vitro and in vivo. Inhibition of PAK1 induces differentiation and apoptosis of AML cells through downregulation of the MYC oncogene and a core network of MYC target genes. Importantly, we find that inhibition of PAK1 inhibits primary human leukemic cells including immature leukemic stem cell-enriched populations. Moreover, we find that PAK1 upregulation occurs during disease progression and is relevant for patient survival in MDS. Our studies highlight PAK1 as a novel target in AML and MDS and support the use of PAK1 inhibitors as a therapeutic strategy in these diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据